Max Mobility Expands Recall of SmartDrive Speed Control Dial Due to Safety Risks

Max Mobility, LLC, in coordination with Permobil, has announced an expanded voluntary recall of its Speed Control Dial, a wired accessory for the SmartDrive MX2+ Power Assist Device. The expanded action addresses safety and performance concerns linked to a material issue with the device’s printed circuit board. The recall now includes all Speed Control Dials manufactured and distributed from August 17, 2023, through March 10, 2025, following the discovery that some older, recalled units may have been mixed with redesigned products and shipped after the initial recall announcement on December 20, 2024.

According to the company, the affected Speed Control Dials may cause the SmartDrive motor to act unpredictably—continuing to run despite attempts to stop it, activating without user input, or failing to start or maintain power. These malfunctions pose a potential hazard to users and those nearby. As of March 27, 2025, Max Mobility/Permobil had received 781 complaints and five reports of serious injury related to these issues. Injuries reported include bone fractures and a concussion.

The Speed Control Dial, identified by model numbers MX2-3DCK and MX2-3DC, is designed to mount directly onto a wheelchair for easy access and control of the SmartDrive system. Due to the severity of the performance failures, the company urges users to stop using the affected dials immediately and switch to alternate control methods, including wired or wearable options, such as compatible smartwatches.

Users and dealers are instructed to use the designated online portal to initiate the replacement process, verify receipt and installation of the new units, and confirm the disposal or return of the defective components. Dealers may choose to notify end users directly or submit user contact information through the portal. Max Mobility/Permobil’s technical support team is available on weekdays to assist users navigating the recall and replacement process.

This action has been reported to the U.S. Food and Drug Administration and is considered a voluntary field correction. Users experiencing adverse reactions are encouraged to report them via the FDA MedWatch program online, by mail, or by fax.

Article by multiple RFHC contributors, based upon information from a press release issued by Max Mobility/Permobil and published by the U.S. Food and Drug Administration.

Video Spotlight